A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

• Status: Suspended
• Trial end date: 2099-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Diego
• Treatments: Fenretinide

Criteria

Inclusion Criteria:

• BMI >30

Exclusion Criteria:

• Diabetes Requiring Medication

• Poorly Controlled Co-Morbidities